Catalent Pharma Solutions
About Catalent Pharma Solutions
Certifications
Categories

-
US
-
2015On CPHI since
-
1Certificates
-
5000+Employees
Company types
Meet us at
CPHI North America 2023
Pennsylvania Convention Center, Philadelphia
April, 25-27, 2023
CPHI Barcelona 2023
Fira Barcelona Gran Via, Spain
24-26 October 2023
Products from Catalent Pharma Solutions (4)
-
Product Catalent Spray Drying Technology
Poorly soluble compounds continue to make up a large share of the pharmaceutical development pipeline. Spray drying has been proven for particle size engineering and known to improve the bioavailability of poorly soluble compounds.
A spray dried dispersion (SDD) is an amorphous molecular dispers... -
Product Dry Powder Inhalation (DPI)
Catalent provides development and manufacturing services for Dry Powder Inhaler (DPI) capsules. With support for clinical- and commercial-scale, the team can handle projects at any stage. Catalent’s Boston-area DPI capsule manufacturing facility is equipped with modern, top-tier encapsulation and... -
Product EasyBurst® Chewable Softgels
CHEWABLE SOFTGEL PLATFORM THAT OFFERS A WIDE RANGE OF SHELL TEXTURES & FLAVORED FILLS FOR GREAT TASTING CHEWABLE FORMULATIONS -
Product OptiGel® DR Softgel Technology
OptiGel® DR is a softgel technology that is formulated with the naturally derived polymer pectin which combines with gelatin to deliver an enteric release profile in a single-step manufacturing process without the need for coating.
Catalent Pharma Solutions Resources (28)
-
News Early development demand continues to boost prospects for smaller CDMOs: CPHI Worldwide panel
The increasing outsourcing trend among pharmaceutical companies represents a promising opportunity for CDMOs. This panel discussion at CPHI Worldwide touched upon some of the opportunities, hurdles, and trends ahead for the CDMO market -
News Catalent embarks on $230M viral vector expansion project at Harmans campus
By completion at the end of 2022, the campus will accommodate 18 cGMP viral vector manufacturing suites -
News Catalent boosts nutraceuticals market presence with $1 billion Bettera acquisition
The transaction is expected to accelerate Catalent's growth in global softgel and oral dose formulation and manufacturing services -
Whitepaper Catalent Oral Technology - Case Study Title: Expediting Path to Clinic with OptiForm® Total Supply
MGB Biopharma (MGB), a biotech company based in Scotland, U.K., is developing a new class of anti-infective medicine based on Minor Groove Binder compounds. MGB-BP-3, a novel small molecule is currently in Phase 2a in the U.S. and Canada. The drug is being developed for the treatment of Clostridium difficile-associated diarrhea. The Catalent sites located in San Diego, CA and Kansas City, MO offered a tablet formulation as a solution to MGB’s needs ,in the form of OptiForm® Total Supply, allowing the integration of formulation development, clinical trial material (CTM) manufacturing, and supply and distribution to patients. Within five months, the first clinical trial kits were successfully delivered to MGB’s patients. -
News DisperSol signs up Catalent for manufacturing of multiple pharma products
The collaboration will see Catalent install a commercial-scale KinetiSol technology manufacturing line at its Somerset, New Jersey, facility -
Video Catalent Consumer Health - OTC Trends, Monograph Reform, and Innovation
OTC Trends, Monograph Reform, and Innovation -
News Catalent plans $100 million biologics manufacturing expansion at Anagni
Two 2,000-liter single-use bioreactors to be installed as part of first phase expected to be operational in April 2023 -
Podcast Podcast: Catalent Cell & Gene Therapy, the Journey
In a little over a year, Catalent has expanded into the Cell and Gene therapy space through acquisitions. In this podcast you will hear from Colleen Floreck, Sr. Director, Strategy & Marketing, Cell & Gene Therapy, about Catalent’s journey into this exciting and growing space, overcoming challenges, and the company’s commitment to its partners. -
News Catalent enters CBD anaesthetic product formulation project
The company will use its orally disintegrating tablet technology Zydis for JOS Pharmaceuticals' licensed CBD product -
News Catalent Acquires Additional Facility at its Gosselies, Belgium Campus for Commercial-Scale Plasmid DNA Manufacturing
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Promethera Biosciences, the leader in advanced therapy development for severe liver diseases, today announced that Catalent has acquired Promethera’s cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS), including its 32,400 square-foot (3,010 square-meter) facility in Gosselies, Belgium. The facility will accommodate Catalent’s new commercial-scale plasmid DNA (pDNA) manufacturing and will provide the opportunity for the immediate growth of Catalent’s pDNA service offering, which was recently acquired from Delphi Genetics to support the growing cell and gene therapy pipeline. -
News Catalent buys Belgian CDMO to boost pDNA manufacturing and service offering
New facility at Gosselies site will host commercial scale pDNA manufacturing as Catalent extends its cell and gene therapy footprint -
News Pharma ramps up innovation in response to COVID-19
CPHI asks industry experts at Beximco Pharmaceuticals, Catalent, DIA and Thermo Fisher Scientific to weigh in on the remarkable innovations we have witnessed and what lasting impacts they may have on our industry in a post-pandemic world -
News Building supply chain resiliency to ensure access to medicines
With CPHI North America fast approaching, we ask Karen Flynn (President, Biologics & Chief Commercial Officer, at Catalent), Hamilton Lenox (Senior Vice President of Business Development, Sales & Marketing, at LGM Pharma), and Mike Kleppinger, Chief Commercial Officer, at AMRI) to weigh in on strategies the industry can use to build supply chain resiliency which ensure uninterrupted access to medicines -
News Catalent boosts plasmid DNA manufacturing at Rockville with addition of ABEC fermenters
The company's custom single run single-use fermenters supplied on fast-track schedule to support flexible manufacturing of plasmid DNA -
News Moderna and Catalent expand COVID vaccine manufacturing agreement
The extended collaboration comes after reaching the initial milestone of producing 100 million doses -
News Catalent signs ODT technology development agreement with Cybin
The CDMO's Zydis technology will help the Canadian biotech to develop fast-acting, shorter-duration formulations of its potential therapy for treatment-resistant psychiatric disorders -
News Catalent takes double action to boost cell and gene therapy services
The company acquires a pDNA CDMO and launches pDNA development and manufacturing services at its Rockville, Maryland facility -
News Catalent secures softgels commercial supply agreement with Aurinia
The CDMO will manufacture recently FDA-approved Lupkynis as a softgel dosage form at its St Petersburg, Florida, facility -
News Catalent secures Trizell cell therapy development and manufacturing contract
The agreement allows the CDMO to "stay on the forefront of emerging indications and cell types" -
News Catalent starts manufacture of Passage Bio's lead gene therapy products
The CDMO will provide packaging, labeling and distribution services through its FastChain demand-led supply offering -
News Catalent signs commercial supply agreement with Blueprint Medicines
The agreement comes hot on the heels of FDA approval of Gavreto — Blueprint Medicines' new treatment for lung cancer -
News Catalent Invests $130 Million to Add Additional Manufacturing Capacity at its Gene Therapy Campus in Harmans, Maryland
Catalent today announced that it is investing $130 million to add five additional Phase 3 through commercial-scale manufacturing suites to its gene therapy campus in Harmans, Maryland. -
News Catalent Supports Rapid Development and Supply of Nocion Therapeutics’ Clinical Trial Materials for Acute and Chronic Cough Using Blow-Fill-Seal Technology
Catalent today welcomed the news from Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule charged sodium channel blockers, that its first patient has been dosed with NOC-100, an inhaled formula of its NTX-1175 small molecule candidate. -
News Catalent Supply Services To Open New Clinical Supply Facility In San Diego
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced it is to invest $9 million in a new clinical supply facility in San Diego, due to open in the summer of 2020. -
News Catalent Launches OneXpress™ Solution to Accelerate Oral Dosage Products from Clinic to Launch
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced the launch of its new OneXpress™ service for the integrated development, scale up and manufactur...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance